Current status and prospects of immunotherapy for locally advanced nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma arising from the nasopharyngeal epithelium, which is associated with Epstein-Barr virus (EBV) infection and is most common in southern China. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), provides favorable efficacy with...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Guangxi Medical University
2024-09-01
|
| Series: | Guangxi Yike Daxue xuebao |
| Subjects: | |
| Online Access: | https://journal.gxmu.edu.cn/article/doi/10.16190/j.cnki.45-1211/r.2024.09.009 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma arising from the nasopharyngeal epithelium, which is associated with Epstein-Barr virus (EBV) infection and is most common in southern China. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), provides favorable efficacy with a good safety profile in a variety of solid tumors, including recurrent or metastatic NPC (R/M-NPC). In addition, immunotherapy has made new breakthroughs in the treatment of locally advanced NPC, and many clinical studies are underway. Based on previously reported results, this study presents a comprehensive overview of the advances and challenges by introducing the basic principles and the current status of immunotherapy in NPC, with the expectation that it will serve as a reference for clinical practice in the future. |
|---|---|
| ISSN: | 1005-930X |